 |
CANCER & TREATMENTS SUPPORT & SURVIVORSHIP PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER | |
| ||
|
|
LeadershipMax S. Wicha, M.D.
Dr. Wicha also serves as the distinguished professor of oncology, professor of internal medicine and is nationally known for his research in the field of breast oncology, particularly the study of how breast cancer cells grow and metastasize. His lab was part of the team that first discovered stem cells in breast cancer, the first described in any human solid tumor. Since then, Dr. Wicha has become one of the leading experts on cancer stem cells, with his continued work on breast cancer stem cells. He has also led efforts within the UMCCC to expand these findings into other tumor types. U-M researchers were first to discover stem cells in pancreatic and head and neck cancers and are focusing on cancer stem cells in virtually every cancer type, including colon, lung and thyroid tumors. Dr. Wicha is also active as a clinician, specializing in the treatment of breast cancer patients. He has served as chairman of the board of the Association of American Cancer Institutes and as past chairman for the National Cancer Institute's Cancer Center Support Review Committee. Dr. Wicha joined the University of Michigan Medical Center in 1980. From 1984 to 1993, he served as chief in the Division of Hematology/Oncology in the Department of Internal Medicine. Dr. Wicha received his medical degree from Stanford University and trained in internal medicine at the University of Chicago. He then went on to the National Cancer Institute, where he trained in clinical oncology and cancer biology.
Dr. Blayney's career has been marked by distinguished volunteer efforts with several prestigious national
health care associations, including the American Society of Clinical Oncology (ASCO), where he has served on the
Board of Directors as well as the Committees on Clinical Practice, Cancer Education, and Online, and the Food and
Drug Administration’s Oncologic Drugs Advisory Committee. Currently, he is the editor of the
Journal of Oncology Practice and board member of the National Comprehensive Cancer Network (NCCN).
Alfred E. Chang, M.D. Dr. Chang has special expertise in the treatment of melanomas, breast cancers and gastrointestinal cancers. He was formerly the director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center and is currently the director of the Gastrointestinal Oncology Research Program at the Center. Dr. Chang is on numerous editorial boards of journals dealing with clinical research, surgical oncology and tumor immunology. Prior to coming to the University of Michigan Health System, he was a senior investigator in the Surgery Branch of the National Cancer Institute. Dr. Chang received his medical degree from Harvard Medical School and completed his surgical residency at Duke University and the University of Pennsylvania, with an intervening surgical oncology fellowship at the National Cancer Institute.
Eric R. Fearon, M.D., Ph.D., associate director for basic science research and Maisel professor of oncology, is responsible for coordinating studies of the mechanisms underlying cancer development, as well as the translation of laboratory observations to clinical applications in the diagnosis and management of cancer. A nationally recognized expert in the field of cancer genetics, Dr. Fearon also serves as co-director of the Cancer Centers Genetics Research Program, which focuses on identifying the genetic alterations and gene expression changes that underlie the development of cancer. In addition, the Program strives to apply the emerging information to improve risk assessment, prevention, pre-symptomatic diagnosis, early detection, and therapy of cancer. Dr. Fearon's research focuses on the nature and role of genetic alterations and gene expression changes in colorectal and other cancers of the gastrointestinal tract. He holds a primary appointment in the Department of Internal Medicine, Division of Medical Genetics, and joint appointments in the departments of Human Genetics and Pathology at the University of Michigan. Dr. Fearon is an editorial board member or editor for a number of scientific journals. Prior to joining the faculty at the University of Michigan in 1995, Dr. Fearon was an assistant professor at Yale University School of Medicine. He received his medical and research degrees and was a postdoctoral fellow at Johns Hopkins University in Baltimore.
Theodore S. Lawrence, M.D., Ph.D. Theodore S. Lawrence, M.D., Ph.D., Isadore Lampe professor of radiation oncology, is the chair of the Department of Radiation Oncology and a professor in the Department of Environmental Health, School of Public Health. He is co-chair of the Radiation Sciences Program and head of the Experimental Irradiation Core of the Cancer Center. On a national level, he is the chair of the National Cancer Institute Board of Scientific Councilors and a member of the Institute of Medicine. He is an editor of The Cancer Journal: Journal of the Principles and Practice of Oncology. Dr. Lawrence is a past president and chairman of the board of the American Society for Therapeutic Radiology and Oncology (ASTRO), the chief professional society for radiation oncology, and a past member of the Board of Directors of ASCO. Dr. Lawrence's interests in the laboratory are focused on chemotherapeutic and molecularly targeted radiosensitizer. His clinical research combines these laboratory studies with conformal radiation guided by metabolic and functional imaging for the treatment of patients with gastrointestinal and central nervous system malignancies. Dr. Lawrence joined the faculty of the University of Michigan in 1987, following a fellowship in medical oncology and a residency in radiation oncology at the National Cancer Institute. He received his research degree in cell biology from the Rockefeller University in New York, followed by his medical degree from Cornell University and an internal medicine residency at Stanford University.
Kenneth J. Pienta, M.D. Kenneth J. Pienta, M.D., professor of medicine and surgery, serves as the Cancer Center’s associate director for the Specialized Program of Research Excellence (SPORE) grant in prostate cancer. As the principal investigator of the $12 million National Cancer Institute grant, Dr. Pienta is responsible for overseeing multidisciplinary efforts to prevent, diagnose and treat prostate cancer. Dr. Pienta also serves as co-director of the Cancer Center's Urologic/Prostate Oncology Research Program. His research interests include understanding the process of prostate cancer metastasis to bone, discovering novel drug combinations to treat hormone refractory prostate cancer, and developing approaches aimed at improving the quality of life of patients with advanced prostate cancer. Dr. Pienta joined the Cancer Center in 1994. Previously, he was assistant professor at Wayne State University School of Medicine and deputy director of the Urologic Oncology Program at the Meyer L. Prentis Comprehensive Cancer Center in Detroit. He received his medical degree and was a postdoctoral fellow at Johns Hopkins University in Baltimore.
Internationally known for his role in the development of targeted cancer therapeutics, Dr. Talpaz pioneered the study of interferon in CML, which was the first line therapy for CML until the introduction of STI571 (Gleevec). As a pivotal member of the team that developed Gleevec, Dr. Talpaz was instrumental in bringing to market one of the most effective targeted treatments used to date in cancer care. As a leader in the development of novel therapeutics, Dr. Talpaz has unique experience in the building of Phase I clinical trial programs. In addition to expanding U-M’s program in hematologic malignances, he will be establishing a Phase I therapeutics program at the Cancer Center. Dr. Talpaz joined U-M in 2006, from M.D. Anderson Cancer Center in Houston, where he was professor of medicine and held the David Bruton Chair for Cancer Research. He has authored or co-authored nearly 400 articles in top national journals and textbooks, and is a member of the American Society of Hematology and the NCCN Chronic Myelogenous Leukemia Guidelines Panel.
Stephen Gruber, M.D., Ph.D., M.P.H., H. Marvin Pollard Professor of Internal Medicine, is a professor of internal medicine and human genetics at the Medical School, and professor of epidemiology at the School of Public Health. Dr. Gruber is the director of Clinical Cancer Genetics and co-director of the Biomedical Prevention program at the Cancer Center. Dr. Gruber's clinical practice focuses on the prevention of cancer in high-risk families. His research is devoted to understanding the contributions of environmental and genetic risk factors to cancer susceptibility. Dr. Gruber is the principal investigator of the Molecular Epidemiology of Colorectal Cancer study, a large, international study of populations in Israel. Dr. Gruber received his medical degree and completed his training in internal medicine from the University of Pennsylvania. His doctorate in epidemiology is from Yale University. He completed a fellowship in medical oncology and cancer genetics at Johns Hopkins University and a medical genetics residency at U-M. Dr. Gruber's research program emphasizes cancer prevention in high-risk populations.
Jeremy M.G. Taylor, Ph.D. Jeremy M.G. Taylor, Ph.D., Pharmacia Research Professor of Biostatistics in the School of Public Health and of radiation oncology in the Medical School, is associate director for biostatistics of the Cancer Center. As the director of the Biostatistics Unit, Dr. Taylor is responsible for collaborating with research scientists within the Cancer Center on the design of studies and the evaluation and interpretation of scientific data. Dr. Taylor's own research focuses on developing statistical methods used in cancer research, with specific interest in longitudinal data analysis, surrogate markers, survival analysis, biomarkers and functional genomics. He is a fellow of the American Statistical Association. Prior to joining the Cancer Center in 1998, Dr. Taylor was professor-in-residence in the Department of Radiation Oncology and the Department of Biostatistics at the University of California Los Angeles. He was the 1996 winner of the Michael Fry Research Award from the Radiation Research Society and the Mortimer Spiegelman Award from the American Public Health Association. Dr. Taylor received his doctoral degree in statistics from the University of California, Berkeley.
Kathleen Cooney, M.D. Kathleen A. Cooney, M.D., Professor of Internal Medicine and Urology, and the Division Chief of Hematology/Oncology. She also serves at the Co-Director of the Cancer Center's Urologic/Oncology Program, Co-Principal Investigator of the SPORE grant in prostate cancer and Associate Director for Faculty Affairs for the Cancer Center. Dr. Cooney is a leading expert in hereditary prostate cancer. She is the Principal Investigator of the University of Michigan Prostate Cancer Genetics Project which is a large family-based study of hereditary prostate cancer with over 3,000 participants. Her research focuses on clinically-relevant questions in the genetic epidemiology of prostate cancer. She is a member of the Steering Committee for the International Consortium for Prostate Cancer Genetics. Dr. Cooney is also an active clinician specializing in the treatment of patients with prostate or bladder cancer. Dr. Cooney joined the faculty in 1991 after completing her residency and fellowship training at the University of Michigan. Her postdoctoral research was conducted in the laboratory of Dr David Ginsburg. Prior to coming to Michigan, she received her medical degree from the University of Pennsylvania.
Marcy Bohm Waldinger, M.H.S.A., oversees all divisions of administration including clinical operations, patient support services, cancer registry, business and finance, research administration, marketing communications and development. She was integrally involved in planning the Cancer Center’s nine-story building and is responsible for its clinical and research administration, and space management. As a member of the Cancer Center Senior Leadership, Ms. Waldinger functions as a chief operation officer with responsibility to ensure that all aspects of Cancer Center administration function effectively to support the programmatic, financial and management needs of the Center. Ms. Waldinger is a founding board member of the National Comprehensive Cancer Network (NCCN) and chairs its
Best Practices Committee. She is also a member and former board member of the Cancer Center Administrators Forum.
She serves as the sole administrator on the Scientific External Advisory Boards of eleven academic cancer centers
nationwide, including Dana-Farber/Harvard Cancer Institute, Fred Hutchinson Cancer Research Center, M.D. Anderson
Cancer Center, University of California Los Angeles, University of California San Francisco and Vanderbilt University. Ms. Waldinger joined the Cancer Center in 1992, and has served in an administrative capacity at the University of Michigan Medical Center since 1980. She received both her undergraduate and graduate degrees from the University of Michigan. Her master's degree in health services administration was obtained from the University of Michigan School of Public Health in 1980.
Gregory T. Wolf, M.D., F.A.C.S. Gregory T. Wolf, M.D., professor and chair of Otolaryngology/Head and Neck Surgery at the University of Michigan, serves as the Cancer Center's Associate Director for the Specialized Program of Research Excellence (SPORE) grant in head and neck cancer. As the principal investigator of the $12 million National Cancer Institute grant, Dr. Wolf is responsible for overseeing the administrative and scientific direction of this multidisciplinary, translational research program examining the molecular basis of head and neck cancer. Dr. Wolf has been principal investigator and study chairman of several national multi-institutional clinical trials which are investigating the use of induction chemotherapy for organ preservation in head and neck cancer. His main research interests have been in tumor immunology, immunotherapy and cell biology, and his clinical trial research has included studies of immunotherapy and chemotherapy regimens. Dr. Wolf received national recognition as study chairman of two large prospective randomized trials that have provided the foundation for changing the standard therapy for patients with advanced laryngeal cancers. Prior to joining the faculty of the University of Michigan in 1980, Dr. Wolf completed a two-year immunology fellowship at the National Institutes of Health. He received his medical degree from the University of Michigan followed by postgraduate training in otolaryngology and general surgery at the State University of New York, Upstate Medical Center in Syracuse, and Georgetown University. -updated 05/09 |
|
See Also:
University of Michigan Comprehensive Cancer Center © 2009 Regents of the University of Michigan / Developed & maintained by: Public Relations & Marketing Communications. Contact Us or UMHS. The information presented is not a tool for self diagnosis or a substitute for professional care. |
|
| |||||
Douglas W. Blayney, M.D.
Eric R. Fearon, M.D., Ph.D.
Moshe Talpaz, M.D.
Stephen Gruber, M.D., Ph.D., M.P.H.
Marcy Bohm Waldinger, M.H.S.A.
